Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.48 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.48 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118552 | 1.00 | SIRT2 (0.49) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL5090302 | 0.99 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Bromide SCHEMBL5514450 | 0.99 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30056078 | 0.99 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15769691 | 0.99 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride Ion SCHEMBL4594160 | 0.99 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride SCHEMBL28343187 | 0.97 | SIRT2 (0.47) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride Ion SCHEMBL15769690 | 0.97 | SIRT2 (0.47) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride SCHEMBL15769692 | 0.96 | SIRT2 (0.46) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL23045030 | 0.95 | SIRT2 (0.45) | SIRT2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739339-A1 | IMMUNOTHERAPY FOR THE TREATMENT OF PRAME-EXPRESSING CANCERS | Focus Fund-Isa LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| EP-4731212-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | Sagimet Biosciences Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4601685-A1 | MODIFIED LONG PEPTIDES SUITABLE FOR USE IN IMMUNISATION | Isabella Pharma B.V. (NL) | 2025-08-20 | — | — | EP | disclosed |
| EP-4551566-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025008085-A1 | IMMUNOTHERAPY FOR THE TREATMENT OF PRAME-EXPRESSING CANCERS | ISA PHARMACEUTICALS B.V. (NL) | 2025-01-09 | — | — | WO | disclosed |
| WO-2024263785-A1 | COMBINATION THERAPIES OF FASN INHIBITORS WITH THYROID HORMONE RECEPTOR AGONISTS | SAGIMET BIOSCIENCES INC. (US) | 2024-12-26 | — | — | WO | disclosed |
| US-20240158768-A1 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | GEMVAX & KAEL CO., LTD. (KR) | 2024-05-16 | — | — | US | disclosed |
| WO-2024079311-A1 | MODIFIED LONG PEPTIDES SUITABLE FOR USE IN IMMUNISATION | ISA PHARMACEUTICALS B.V. (NL) | 2024-04-18 | — | — | WO | disclosed |
| WO-2024008941-A1 | NEW SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2024-01-11 | — | — | WO | disclosed |
| EP-4277892-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | Les Laboratoires Servier (FR) | 2023-11-22 | — | — | EP | disclosed |
| EP-4232189-A1 | NANOFILTRATION ASSISTED METHODS OF CHEMICAL SYNTHESIS | Bachem AG (CH) | 2023-08-30 | — | — | EP | disclosed |
| EP-4100051-A2 | TREATMENT OF HPV-RELATED DISEASES | ISA Pharmaceuticals B.V. (NL) | 2022-12-14 | — | — | EP | disclosed |
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | SAGIMET BIOSCIENCES INC. | 2022-10-27 | — | — | US | disclosed |
| WO-2022152705-A1 | SPIROCYCLOHEXANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USES AS ANTI-APOPTOTIC INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2022-07-21 | — | — | WO | disclosed |
| EP-4017850-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017849-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| EP-4017587-A1 | ENZYME INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-29 | — | — | EP | disclosed |
| EP-4010333-A1 | PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2022084441-A1 | NANOFILTRATION ASSISTED METHODS OF CHEMICAL SYNTHESIS | BACHEM AG (CH) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340556-A1 | HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS | FASN, FADS1, FADS2 | SIRT2 761/4885HDAC3 613/4885HDAC4 740/4885 |
| US-20240158768-A1 | ANTI-INFLAMMATORY PEPTIDES AND COMPOSITION COMPRISING THE SAME | IL1B, IL1A, TNF | SIRT2 4142/4885HDAC3 4154/4885HDAC4 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.